CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy

Overview of attention for article published in Journal of Clinical Oncology, March 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 9 news outlets
blogs: 1 blog

twitter: 42 X users
reddit: 1 Redditor

Readers on

mendeley: 52 Mendeley

So far, Altmetric has seen 48 X posts from 42 X users, with an upper bound of 227,303 followers.

📉 A negative trial in mNSCLC highlights the poor prognosis of these patients even in modern-day clinical trials: Atezolizumab + cabozantinib showed no OS benefit over docetaxel. Read more here: https://t.co/FlDO2FFvUZ #NSCLC #ClinicalTrials #Trialing

CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy https://t.co/KYSdunci6C

RT @SCIDirector: SCI member @JoelNealMD & others found no significant improvement in overall survival with atezolizumab +cabozantinib vs do…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 44 additional X posts.